DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Tailored Smoking Cessation Treatment for LIVE FOR LIFE® Participants

Information source: Duke University
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Cigarette Smoking; Nicotine Dependence

Intervention: varenicline (Chantix) (Drug); bupropion (Zyban) (Drug); nicotine patches (Drug)

Phase: Phase 2/Phase 3

Status: Terminated

Sponsored by: Duke University

Official(s) and/or principal investigator(s):
Jed E Rose, Ph.D., Principal Investigator, Affiliation: Duke University

Summary

The purpose of this study is to ascertain: 1) the rate of smoking cessation obtained using an adaptive treatment algorithm developed in previous clinical trials, in order to calculate cost-effectiveness of the treatment; 2) the relationship between genotype and response to cigarette smoking cessation treatment.

Clinical Details

Official title: Tailored Smoking Cessation Treatment for LIVE FOR LIFE® Participants

Study design: Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Primary outcome: Cost-effectiveness of the Adaptive Treatment Approach to Smoking Cessation

Secondary outcome: Quit Success Genotype Score

Detailed description: Previous research has shown that the initial response to nicotine patch treatment can be used to decide whether the patch alone is likely to help smokers to quit or whether alternative prescription medications may be needed to achieve smoking abstinence. This study applies the knowledge gained from this previous research to adapt the smoking cessation treatment provided to participants, based on their degree of smoking reduction during the first four weeks of nicotine patch treatment. By demonstrating effectiveness of this algorithm, this study may lead to further dissemination of the adaptive treatment strategy to other health care settings. Additionally, by gathering further information relating genomic markers to outcome, the foundation will be laid for potential practical application of this index in other settings.

Eligibility

Minimum age: 18 Years. Maximum age: 65 Years. Gender(s): Both.

Criteria:

Inclusion Criteria:

- Duke employees who are enrolled in a Duke Health Plan and intend to remain employed

at Duke for the next six months;

- Dependents of Duke employees who meet the above criteria;

- 18-65 years old;

- Currently smoke an average of at least 10 cigarettes per day;

- Willing to take Chantix or Zyban;

- Express a desire to quit smoking within the next 30 days.

Exclusion Criteria:

- Hypertension;

- Hypotension with symptoms (systolic <90 mm Hg, diastolic <60 mm Hg);

- Coronary heart disease;

- Lifetime history of heart attack;

- Cardiac rhythm disorder (irregular heart rhythm);

- Chest pains (unless history, exam, and ECG clearly indicate a non-cardiac source);

- Cardiac (heart) disorder (including but not limited to valvular heart disease, heart

murmur, heart failure);

- Extensive active skin disorder;

- Liver or kidney disorder (except kidney stones, gallstones);

- Gastrointestinal disease other than gastroesophageal reflux or heartburn;

- Active ulcers in the past 30 days;

- Currently symptomatic lung disorder/disease (including but not limited to COPD,

emphysema, and asthma);

- Brain abnormality (including but not limited to stroke, brain tumor, and seizure

disorder);

- Migraine headaches that occur more frequently than once per week;

- Recent, unexplained fainting spells;

- Diabetes treated with insulin; non-insulin treated diabetes (unless glucose is less

than 180mg/dcl and HbA1c is less than 7%);

- Current cancer or treatment for cancer in the past six months (except basal or

squamous cell skin cancer);

- Other major medical condition;

- Suicidal ideation (within the past 10 years) or lifetime occurrence of attempted

suicide;

- Pregnant or nursing mothers;

- Current psychiatric disease (with the exception of anxiety disorders, OCD and ADHD);

- Current depression;

- Bulimia or anorexia;

- Alcohol abuse;

- Significant adverse reaction to bupropion/Wellbutrin/Zyban, Chantix/Varenicline or

nicotine patches in the past.

- Use (within the past 30 days) of:

- Wellbutrin, bupropion, Zyban, Chantix, nicotine replacement therapy or any other

smoking cessation aid.

- Medications that are known to affect smoking cessation.

Locations and Contacts

Duke Center forSmoking Cessation, Durham, North Carolina 27705, United States

Duke Center for Smoking Cessation, Raleigh, North Carolina 27609, United States

Additional Information

Starting date: May 2012
Last updated: December 5, 2014

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017